Plain-English translation of NCT07422519 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This study doesn't follow the usual testing phases โ it may be an observational study or a different type of research.
This trial is testing whether combining esketamine (a medication already approved for hard-to-treat depression) with virtual reality-based mindfulness sessions works better than the medication alone. You'd receive the medication as usual, but half of participants will also do 10-minute guided mindfulness sessions in a virtual reality environment right before each dose. The researchers want to see if adding this mindfulness component helps people feel better and recover more fully.
Many people with severe depression don't respond well enough to standard antidepressants, and doctors don't have a clear best approach for these patients. While this medication has helped some people, researchers think combining it with a psychological tool like mindfulness might give patients a better chance at real improvement by working on both the brain chemistry and coping skills at the same time.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would receive intranasal esketamine doses over 30 weeks, divided into an induction phase (weeks 1โ4) and a maintenance phase (weeks 5โ30). If you're in the mindfulness group, you'd also do a 10-minute guided virtual reality mindfulness session immediately before each esketamine dose during the first four weeks, and continue with the mindfulness sessions during the rest of the study. You'd attend multiple clinic visits to receive the medication and mindfulness sessions, and your depression symptoms would be monitored throughout.
AI-generated summary from trial data ยท Jul 5, 2026 ยท Not medical advice
Spain